Carsten Boess
CIK 1277495 · SVP, Chief Financial Officer · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GEVA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RCKT | Director | 52,862 | $2.28 | $120.5K | $0 | 6 | 2026-07-06 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Director | 0 | — | — | $0 | 1 | 2026-02-27 |
| ROCKET PHARMACEUTICALS, INC. (RCKTW) Delisted | Director | 30,000 | $0.00 | $60 | $0 | 3 | 2025-07-18 |
| RNA | Director | 6,692 | $8.05 | $53.9K | $0 | 5 | 2025-06-12 |
| KNSA | 10%+ Owner | 79,589 | $72.98 | $5.81M | $0 | 1 | 2018-05-29 |
| ROCKET PHARMACEUTICALS, INC. (ITEK) Delisted | Director | — | — | — | $0 | 3 | 2017-06-21 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | SVP, Chief Financial Officer | 0 | — | — | -$12.17M | 17 | 2015-06-23 |
| PODD | Vice President, International | 18,941 | $149.26 | $2.83M | -$4.81M | 16 | 2011-04-27 |
Recent Filings · Page 5 of 6
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-03-31 | PODD | Mixed | — | -$592.1K | EDGAR |
| 2011-03-25 | PODD | Mixed | — | -$546.4K | EDGAR |
| 2011-03-03 | PODD | Mixed | +8,941 | -$18.5K | EDGAR |
| 2011-02-09 | PODD | Mixed | — | -$47.8K | EDGAR |
| 2011-02-04 | PODD | Mixed | — | -$309.7K | EDGAR |
| 2011-01-20 | PODD | Mixed | — | -$111.3K | EDGAR |
| 2010-10-07 | PODD | Sell (S) | −23,240 | -$349.2K | EDGAR |
| 2010-03-03 | PODD | Grant (A) | +10,000 | $0 | EDGAR |
| 2009-03-02 | PODD | Grant (A) | — | $0 | EDGAR |
| 2008-11-13 | PODD | Buy (P) | +23,240 | $117.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.